e-Drug3D

362

CLOFIBRATE

DISCONTINUED


INN
CLOFIBRATE

(has an active metabolite)

cas 637-07-0
CLASS

CARDIOVASCULAR
HYPOLIPIDEMIC
ANTICHOLESTEREMIC AGENTS
ANTILIPIDEMIC AGENTS
REDUCE THE VERY LOW-DENSITY LIPOPROTEIN FRACTION

ROUTE (list)

ORAL

ATC code

C10AB01

PK parameters

Target

TARGET PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR

DrugCentral

Peroxisome proliferator-activated receptor alpha UNIPROT Q07869 PPARA

Download SDF file ethyl 2-(4-chlorophenoxy)-2-methylpropanoate

Formula:
C12H15ClO3

Calculated chemical properties:

MW 242.69
NB_atoms 16
XLogP 3.06
PSA 36.011
NB_HD 0
NB_HA 3
fsp3 0.42
Lipinski(0=no;1=yes) 1

FDA
NDA 072191 (pdf not found) INN (CLOFIBRATE) CLOFIBRATE (SANDOZ) APPROVAL= - YEAR= 0 DISCONTINUED
NDA 016099 (pdf not found) INN (CLOFIBRATE) ATROMID-S (WYETH AYERST) APPROVAL= AP YEAR= 1967 NEWMOLECULARENTITY DISCONTINUED
NDA 070531 (pdf not found) INN (CLOFIBRATE) CLOFIBRATE (USL PHARMA) APPROVAL= AP YEAR= 1986 DISCONTINUED
NDA 071603 (pdf not found) INN (CLOFIBRATE) CLOFIBRATE (WATSON LABS) APPROVAL= AP YEAR= 1987 DISCONTINUED
NDA 072600 (pdf not found) INN (CLOFIBRATE) CLOFIBRATE (TEVA) APPROVAL= AP YEAR= 1991 DISCONTINUED
NDA 073396 (pdf not found) INN (CLOFIBRATE) CLOFIBRATE (BANNER PHARMACAPS) APPROVAL= AP YEAR= 1992 DISCONTINUED

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL